fda compounded semaglutide ban is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Warns on Certain Forms

A 2025 narrative review reached comparable conclusions on the compound's positioning within the broader incretin-class research peptide spectrum (PMID 40563436)

Plants 11, 345

All authors have read and approved the final version of this review

even if the rats were orally administered to their maximum dose (1,600 mg/kg/d), and no adverse reactions occurred (Schauss et al., 2011

Adding TB-500, KPV, or other peptides increases compounding costs and protocol complexity

Here is what FDA public regulatory sources confirm as of May 2026: The FDA removed tirzepatide from its drug shortage list in December 2024 and semaglutide in February 2025